Literature DB >> 15733211

Prediction of drug metabolism and interactions on the basis of in vitro investigations.

Olavi Pelkonen1, Miia Turpeinen, Jouko Uusitalo, Arja Rautio, Hannu Raunio.   

Abstract

Drug metabolism profoundly affects drug action, because almost all drugs are metabolised in the body and thus their concentrations and elimination rates are dependent on metabolic activity. Drug metabolism contributes substantially to interindividual differences in drug response and is also often involved in drug interactions, resulting in either therapeutic failure or adverse effects. Knowledge about the metabolism of a new chemical entity and its affinity to drug-metabolising enzymes helps in the drug development process by providing important information for the selection of a lead compound from among a number of substances pharmacologically equally effective in their therapeutic response. In drug development protocols, metabolism characteristics should be assessed very early during the development process. This has been made possible by the advances made especially in analytical capabilities and in in vitro technologies that are employed to predict in vivo metabolite profile, pharmacokinetic parameters and drug-drug interaction potential.

Mesh:

Substances:

Year:  2005        PMID: 15733211     DOI: 10.1111/j.1742-7843.2005.pto960305.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  16 in total

1.  Use of high-throughput enzyme-based assay with xenobiotic metabolic capability to evaluate the inhibition of acetylcholinesterase activity by organophosphorous pesticides.

Authors:  Shuaizhang Li; Jinghua Zhao; Ruili Huang; Michael F Santillo; Keith A Houck; Menghang Xia
Journal:  Toxicol In Vitro       Date:  2019-01-06       Impact factor: 3.500

2.  In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions.

Authors:  Olavi Pelkonen; Miia Turpeinen; Hannu Raunio
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

3.  Parameterization of Microsomal and Cytosolic Scaling Factors: Methodological and Biological Considerations for Scalar Derivation and Validation.

Authors:  Michael J Doerksen; Robert S Jones; Michael W H Coughtrie; Abby C Collier
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-12-19       Impact factor: 2.441

4.  Tissue-level modeling of xenobiotic metabolism in liver: An emerging tool for enabling clinical translational research.

Authors:  Marianthi G Lerapetritou; Panos G Georgopoulos; Charles M Roth; Loannis P Androulakis
Journal:  Clin Transl Sci       Date:  2009-06       Impact factor: 4.689

5.  Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.

Authors:  Brian F Kiesel; Robert A Parise; Jianxia Guo; Donna M Huryn; Paul A Johnston; Raffaele Colombo; Malabika Sen; Jennifer R Grandis; Jan H Beumer; Julie L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  2016-10-24       Impact factor: 3.333

6.  Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone.

Authors:  Tiina Jaakkola; Janne T Backman; Mikko Neuvonen; Mikko Niemi; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2006-05-03       Impact factor: 2.953

Review 7.  Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools.

Authors:  Naiem T Issa; Henri Wathieu; Abiola Ojo; Stephen W Byers; Sivanesan Dakshanamurthy
Journal:  Curr Drug Metab       Date:  2017       Impact factor: 3.731

Review 8.  Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4.

Authors:  Stéphane Mouly; Christophe Meune; Jean-François Bergmann
Journal:  Intensive Care Med       Date:  2009-01-09       Impact factor: 17.440

9.  Effect of ademetionine on cytochrome P450 isoforms activity in rats.

Authors:  Shuhua Tong; Jiayi Guo; Huanchun Song; Shiwen Lv; Yalan Zhu; Jianshe Ma; Yuancai Zheng
Journal:  Int J Clin Exp Med       Date:  2015-06-15

10.  Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.

Authors:  Marjo J Karjalainen; Pertti J Neuvonen; Janne T Backman
Journal:  Eur J Clin Pharmacol       Date:  2007-07-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.